Normunity, a biotechnology company creating novel anti-cancer therapies, announced that it has closed a Series B financing for $75 million.

The financing was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. The Board of Directors will be expanded to include David Parry, PhD (Samsara), Sara Nayeem, MD (Enavate) and Marie-Clare Peakman, MD (Pfizer Ventures).